CYP1A2 and chronic kidney disease: Regarding hepatic CYP1A2 expression, complex impact of chronic kidney disease was depicted: (1) human uremic serum significantly decreased the expression and the activity of CYP1A2 in rat hepatocytes [18]; (2) in rats, mild or negligible effect of renal impairment on CYP1A2 expression was observed in vivo [21, 51]; (3) in patients with chronic kidney disease, mild or no changes were observed in clearance of CYP1A2 substrates, such as duloxetine, lidocaine or tasimelteon [54].